secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2026-01-23T23:59:59+00:00
Accession:  0001104659-26-006021
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure reports $41.8M cash; SIM0505 data Q2 2026, LNCB74 delayed to H2 2026
-----------------------------------------------------------------------------

- Preliminary cash, cash equivalents and marketable securities of $41.8M as of Dec 31, 2025; runway into H1 2027.
- SIM0505 (CDH6 ADC) Phase 1 dose escalation data expected Q2 2026; dose optimization starts H1 2026.
- LNCB74 (B7-H4 ADC) higher dose cohorts underway; proof-of-concept data delayed from H1 to H2 2026.
- Both programs target gynecological cancers; LNCB74 now includes adenoid cystic carcinoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000110465926006021/0001104659-26-006021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000110465926006021/nxtc-20260123x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-006021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer